Video

Assay for Ductal Carcinoma In Situ

Publish date: January 6, 2012

 

SAN ANTONIO – The Oncology Report's editor-in-chief, Dr. Howard A. Burris III, and its associate editor Dr. William J. Gradishar discuss an ONCOTYPE DX assay for ductal carcinoma in situ at the 2011 San Antonio Breast Cancer Symposium.

Recommended Reading

Less Trastuzumab Cardiotoxicity in Beta-Blocker Users
MDedge Hematology and Oncology
Pegfilgrastim Costly, Unnecessary in Some Breast Cancer Patients
MDedge Hematology and Oncology
Adjuvant Ibandronate: No Gain in Early Breast Cancer
MDedge Hematology and Oncology
Program Curbs Shoulder Morbidity Post Breast Cancer
MDedge Hematology and Oncology
Cancer Death Rates Continue to Drop
MDedge Hematology and Oncology
Do Bisphosphonates Reduce Cancer Risks?
MDedge Hematology and Oncology
Anastrozole and Fulvestrant in Hormone Receptor-Positive Breast Cancer
MDedge Hematology and Oncology
Bisphosphonates as Antitumor Agents in Breast Cancer
MDedge Hematology and Oncology
Community Oncology Podcast - Radiation in breast cancer
MDedge Hematology and Oncology
Retrospective Study of Patients with Metastatic Triple-Negative Breast Cancer: Survival, Health Care Utilization, and Cost
MDedge Hematology and Oncology